XML 103 R72.htm IDEA: XBRL DOCUMENT v3.22.4
Acquisitions and divestments - Text Details (Detail)
€ in Millions
 12 Months Ended
Dec. 31, 2022
EUR (€)
Dec. 31, 2021
EUR (€)
Dec. 31, 2020
EUR (€)
Dec. 30, 2022
EUR (€)
Feb. 09, 2021
$ / shares
Acquisitions and divestments [Line Items]          
Aggregated net cash outflow for acquisitions € 139        
Other non-current financial assets 660 € 630 € 430    
Losses on disposals of other remaining business 109 43 € 30    
Aging & Caregiving [member]          
Acquisitions and divestments [Line Items]          
Other non-current financial assets   40      
Losses on disposals of other remaining business   75      
Acquisitions and divestments [Domain]          
Acquisitions and divestments [Line Items]          
Aggregated net cash outflow for acquisitions 359 2,824      
Contingent consideration recognised as of acquisition date 96        
Goodwill recognised as of acquisition date   2,113   € 307  
Identifiable intangible assets recognised as of acquisition date 179 840      
Deferred tax assets recognised as of acquisition date 20        
Deferred tax liabilities recognised as of acquisition date 43 206      
Remaining two acquisitions [Member]          
Acquisitions and divestments [Line Items]          
Contingent consideration recognised as of acquisition date 61        
Goodwill recognised as of acquisition date 130        
Identifiable intangible assets recognised as of acquisition date 95        
Deferred tax liabilities recognised as of acquisition date 23        
Vesper Medical [Member]          
Acquisitions and divestments [Line Items]          
Goodwill recognised as of acquisition date 177        
Identifiable intangible assets recognised as of acquisition date 84        
Deferred tax assets recognised as of acquisition date 15        
Deferred tax liabilities recognised as of acquisition date (20)        
Cash transferred € 227        
Discount rate applied to cash flow projections 12.00%        
Vesper Medical [Member] | Business combinations [member]          
Acquisitions and divestments [Line Items]          
Discount rate applied to cash flow projections 12.00%        
Vesper Medical [Member] | At fair value [member]          
Acquisitions and divestments [Line Items]          
Contingent consideration recognised as of acquisition date € 34        
Vesper Medical [Member] | Carrying amount [member]          
Acquisitions and divestments [Line Items]          
Contingent consideration recognised as of acquisition date € 44        
BioTelemetry [Member]          
Acquisitions and divestments [Line Items]          
Aggregated net cash outflow for acquisitions   2,132      
Contingent consideration recognised as of acquisition date   (16)      
Goodwill recognised as of acquisition date   1,790      
Identifiable intangible assets recognised as of acquisition date   623      
Deferred tax assets recognised as of acquisition date   77      
Deferred tax liabilities recognised as of acquisition date   (160)      
Cash transferred   € 2,337      
Discount rate applied to cash flow projections   10.00%      
Purchase price per share | $ / shares         $ 72
Settled liabilities, contingent liabilities recognised in business combination   € 172      
Useful life measured as period of time, intangible assets other than goodwill   14 years      
Revenue of acquiree since acquisition date   € 387      
Profit (loss) of acquiree since acquisition date   32      
Acquisition-related costs recognised as expense for transaction recognised separately from acquisition of assets and assumption of liabilities in business combination   40      
Capsule Technologies [Member]          
Acquisitions and divestments [Line Items]          
Aggregated net cash outflow for acquisitions   520      
Goodwill recognised as of acquisition date   322      
Identifiable intangible assets recognised as of acquisition date   217      
Deferred tax assets recognised as of acquisition date   17      
Deferred tax liabilities recognised as of acquisition date   (46)      
Cash transferred   € 539      
Discount rate applied to cash flow projections   12.00%      
Useful life measured as period of time, intangible assets other than goodwill   17 years      
Revenue of acquiree since acquisition date   € 75      
Profit (loss) of acquiree since acquisition date   10      
Acquisition-related costs recognised as expense for transaction recognised separately from acquisition of assets and assumption of liabilities in business combination   € 11